$ENVB Cashflow Statement | Understand Stock

$ENVB

$1.42 +$0.04 (2.9%) Close

$ENVB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From Operating Activities:
Net loss
Adjustments to reconcile net loss to cash used in operating activities
Change in fair value of investment option liability
Change in fair value of derivative liability
Stock-based compensation
Stock issued in lieu of cash for services
Inducement expense
Impairment of intangibles
Non-cash income tax benefit
Deferred offering costs expensed
Amortization of right of use asset
Amortization of intangibles
Depreciation expense
Impairment of intangible assets and goodwill
Gain on disposal of property and equipment
Other
Change in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable, accrued expenses and other liabilities
Right-of-use operating lease liability
Due to related parties
Right-of-use operating lease asset and obligation

Net cash used in operating activities
Purchases of property and equipment
Purchase of Diverse Bio license agreement
Equipment purchases
Cash accretive acquisition of MagicMed
Proceeds from disposal of property and equipment
Net cash provided by investing activities
Cash Flows From Financing Activities:
Proceeds from Common Stock sold for cash pursuant to the ATM Agreement, net of offering costs
Proceeds from the exercise and inducement of Series A, B, C, and D warrants, net of offering costs
Proceeds from Common Stock sold under the Equity Distribution Agreement, net of offering costs
Proceeds from the sale of redeemable non-controlling interest, net of offering costs (see Note 8)
Proceeds from Common Stock sold under the Purchase Agreement, net of offering costs
Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options
Payment for offering costs previously accrued
Payment for equity distribution offering costs
Redemption of Series A Preferred Stock
Proceeds from the sale of redeemable non-controlling interest, net of offering costs
Net cash provided by financing activities

Effect of foreign exchange rate on changes on cash
Net increase (decrease) in cash
Cash at beginning of year
Cash at end of year
Supplemental disclosure of cash flow transactions:
Right-of-use assets obtained in exchange for lease liabilities
Cash paid for interest
Income taxes paid
Warrants issued in conjunction with common stock issuance
Issuance of embedded derivative

Non-cash financing and investing activities:
Issuance of Common Stock pursuant to MagicMed amalgamation
Stock subscription receivable
Non-cash issuance of round-up shares
Deferred tax liability incurred due to MagicMed amalgamation
Conversion of preferred stock to common stock
Fair value of warrants issued
Right-of-use assets obtained in exchange for lease liabilities
Non-cash issuance of RSA vested shares
Offering costs accrued not paid
Warrants issued for offering costs
Deferred offering costs not paid
Deemed dividend on inducement of warrants
Issuance of Placement Agent Warrants as offering costs
Issuance of common shares for offering costs
Deferred offering costs charged to offering costs
Induced conversion of warrants and preferred investment options
Preferred dividends attributable to redeemable non-controlling interest
Investment options issued in conjunction with common stock issuance
Modification of warrants as part of share capital raise
Warrants issued in conjunction with common stock issuance
Accretion of embedded derivative to redemption value

Comments